



Patient Card










IMPORTANT Information for Patients

Carry this card with you at all times to inform healthcare professionals that you are receiving treatment with ipilimumab alone.

 Ipilimumab can increase the risk of serious or even life-threatening side effects, which may affect different parts of the body. If you have any signs or symptoms, tell your doctor right away. This includes any possible side effects not included in this card or in the YERVOY (ipilimumab) Consumer Medicine Information.

POSSIBLE SIDE EFFECTS

	Bowel and stomach	Diarrhoea (watery, loose, or soft stools), bloody or dark-coloured stools, more frequent bowel movements than usual, pain or tenderness in your stomach or abdomen area, nausea or vomiting
	Eye	Redness in the eye, pain in the eye, vision problems, or blurry vision
	Hormone glands	Rapid heartbeat, increased sweating, weight gain or loss, feeling cold, hair loss, constipation, your voice gets deeper, fever, tiredness, headache, dizziness or fainting, feeling more hungry or thirsty than usual, needing to urinate more often, or behavioural changes (eg, less sex drive, being irritable or forgetful)
	Liver	Eye or skin yellowing (jaundice), pain on the right side of your stomach area, dark urine, or bleeding
	Lungs	Shortness of breath, cough, or chest pain
	Nerves	Muscle weakness, numbness or tingling in legs, arms, or face, dizziness, loss of consciousness or difficulty waking up
	Skin	Skin rash with or without itching, dry skin, blisters and/or peeling of the skin, mouth sores, swelling of the face or lymph glands

My Doctor's Contact Information

(who prescribed ipilimumab)

Name of Doctor: _____

Office Phone: _____

After-Hours Phone: _____

My Contact Information

My Name: _____

My Phone Number: _____

Emergency Contact (name and phone number): _____

OTHER IMPORTANT SIDE EFFECTS

Severe infusion reactions:

Reactions to infusing ipilimumab into the bloodstream might occur, usually during or within 24 hours of receiving a dose. Tell your doctor or nurse right away if you get these symptoms: chills or shaking, itching or rash, flushing, difficulty breathing, dizziness, fever, and feeling like passing out.

ADDITIONAL NOTES FOR PATIENTS

- Tell your doctor of any previous medical conditions.
- Early treatment of side effects reduces the likelihood that ipilimumab treatment will need to be temporarily or permanently stopped.
- Signs and symptoms that may appear mild can quickly worsen if left untreated.
- **DO NOT** try to treat these symptoms yourself.
- Signs and symptoms can appear during treatment or may be delayed and may occur weeks to months after your last ipilimumab injection.

For more information, read the YERVOY (ipilimumab) Consumer Medicine Information (www.medsafe.govt.nz/consumers/cmi/y/yervoy.pdf) or call Medical Information on **0800 167 567**.

IMPORTANT Information for Healthcare Professionals

- This patient is treated with ipilimumab monotherapy.
- Immune-related adverse reactions may appear at any time during treatment with ipilimumab or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimise life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific immune-related adverse reactions.
- Healthcare professionals should refer to the YERVOY (ipilimumab) Data Sheet (www.medsafe.govt.nz/profs/datasheet/y/yervoyinj.pdf) or contact Medical Information on **0800 167 567** or medinfo.australia@bms.com for more information.

The healthcare professional treating this patient with ipilimumab should complete the 'My Doctor's Contact Information' section of this Patient Card.

YERVOY® (ipilimumab 5 mg/mL) is a prescription medicine that may be used to treat advanced melanoma. YERVOY® has risks and benefits. Ask your doctor if you have any questions about your treatment with YERVOY®. Use YERVOY® strictly as directed. If symptoms persist or you have side effects, see your doctor. YERVOY® monotherapy is an unfunded medicine. Medicine costs and normal doctor charges will apply.

© 2025 Bristol-Myers Squibb. YERVOY® is a registered trademark of Bristol-Myers Squibb Company. Bristol-Myers Squibb (NZ) Limited, Auckland, New Zealand. BMS Medical Information: 0800 167 567 (toll free) or medinfo.australia@bms.com. 731-NZ-2500001. TAPS: MR12356. Date of preparation: September 2025. BRISOY0010.